Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
CRPC
Advertisement
Latest News
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
![Monitoring [177Lu]Lu-PSMA Therapy in mCRPC: Clinical Protocols](https://mumcdnstorage.blob.core.windows.net/guonc/2022/09/Metastatic-prostate-cancer.jpg)
New research explores the prognostic potential of LuPSMA-SPECT/CT with RECIP 1.0 in patients with advanced prostate cancer.
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
Advertisement
Advertisement
Trending
Drs. Ahmed and Ciuro discuss the real-world quality-of-life improvements patients may experience after de-escalating therapy.
Drs. Ahmed and Ciuro explore the rationale and complexity behind treatment de-escalation in de novo oligometastatic HSPC.
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.